A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Type of Cancer
Leukemia

Site
Sparta

Protocol Number
Celgene Connect MDS

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

FEASIBILITY AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) COMPARED TO CONVENTIONAL THERAPY FOR OLDER AND MEDICALLY INFORM PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC Syndromes: A PROSPECTIVE OBSERVATIONAL STUDY

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Fred Hutch

Protocol Number
Observational

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent